Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
- PMID: 31447592
- PMCID: PMC6682754
- DOI: 10.2147/IJWH.S178349
Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
Abstract
Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited treatment options, namely chemotherapy. Different molecular studies have recently classified TNBC into different subtypes opening the door to potential new-targeted treatment options. In this review, we discuss the current standard of care in the treatment of TNBC in the neoadjuvant, adjuvant and metastatic settings. In addition, we summarize the ongoing phase III clinical trials evaluating different associations between the 3 pillars of anticancer treatment: chemotherapy, targeted therapy and immunotherapy.
Keywords: PARP inhibitors; breast cancer; immunotherapy; triple-negative.
Conflict of interest statement
Matteo Lambertini served as a consultant for Teva and received honoraria from Theramex and Takeda outside the submitted work. All remaining authors declared no conflicts of interest in this work.
Figures
References
LinkOut - more resources
Full Text Sources